Educational disclaimer: This article is intended for educational purposes only. It summarizes findings from published scientific and clinical research on the endocannabinoid system and Parkinson's disease. It does not constitute medical advice, and it is not a recommendation for or against any treatment, supplement, or therapy. Nothing in this article should be interpreted as a claim that cannabinoids treat, manage, or cure Parkinson's disease or any of its symptoms. Readers should speak with their neurologist or movement disorder specialist before making any changes to their care plan.
Parkinson's disease is a progressive neurodegenerative condition marked by the loss of dopamine-producing neurons in a brain region called the substantia nigra, part of a larger network known as the basal ganglia. Because current treatments, primarily levodopa and other dopaminergic therapies, do not address every motor and non-motor symptom of the disease, and because long-term levodopa use is often accompanied by involuntary movements known as levodopa-induced dyskinesia, researchers have spent more than two decades exploring other neurochemical systems that might help explain, or eventually inform approaches to, the disease process. One such system is the endocannabinoid system (ECS), a signaling network present throughout the brain that appears to be particularly dense in the basal ganglia circuitry affected by Parkinson's disease.
This article summarizes what researchers have found so far when studying the ECS in the context of Parkinson's disease. It draws on cell and animal model research, postmortem human tissue studies, brain imaging studies, patient surveys, and a handful of small clinical trials. As will become clear throughout, this is an area of active, ongoing, and often inconclusive investigation. No cannabinoid-based therapy is currently established or approved as a treatment for Parkinson's disease, and the findings described below should be understood as preliminary signals that require further, more rigorous study rather than as evidence of clinical benefit.
Why researchers are interested in the endocannabinoid system
The endocannabinoid system consists of naturally occurring signaling molecules called endocannabinoids (the two most studied being anandamide and 2-arachidonoylglycerol, or 2-AG), the receptors they act on (primarily CB1 and CB2), and the enzymes that build and break these molecules down. CB1 receptors are among the most abundant G-protein-coupled receptors in the mammalian brain, and they are expressed at particularly high density in the basal ganglia, including the striatum, globus pallidus, substantia nigra, and subthalamic nucleus, the same circuitry that is progressively disrupted in Parkinson's disease [1][2].
Within this circuitry, the ECS is thought to act largely as a modulatory system rather than a primary signaling pathway. Endocannabinoids are typically synthesized "on demand" in postsynaptic neurons and travel backward across the synapse to activate CB1 receptors on presynaptic nerve terminals, where they tend to dampen the release of neurotransmitters. In the basal ganglia, this includes both GABAergic transmission (the basal ganglia's primary inhibitory signaling system) and glutamatergic transmission (its primary excitatory signaling system) [1][2]. Because the classic basal ganglia model of Parkinson's disease describes an imbalance between excitatory and inhibitory pathways following dopamine loss, a signaling system positioned to fine-tune both sides of that balance has understandably drawn scientific interest. Researchers have hypothesized that changes in endocannabinoid tone could, at least in theory, be either a compensatory response to dopamine loss or a contributor to some of the downstream circuit dysfunction associated with the disease. Distinguishing between these possibilities, and determining whether either has practical significance, remains an open question [2][3].
It's worth emphasizing that this rationale is largely mechanistic and derived from basic neuroscience. It explains why the ECS is a biologically plausible target for study; it does not, by itself, demonstrate that modulating the ECS produces any clinical benefit in people with Parkinson's disease.
What preclinical research has explored
Much of the foundational work on the ECS in Parkinson's disease has come from animal and cell-based models designed to mimic aspects of the disease, most commonly using neurotoxins such as 6-hydroxydopamine (6-OHDA) or MPTP to selectively damage dopaminergic neurons in rodents or primates.
Several of these studies have reported that dopamine depletion is associated with changes in CB1 receptor expression in the basal ganglia, though the direction and location of these changes have varied depending on the model, the brain region examined, and the stage of the lesion. For example, one study in 6-OHDA-lesioned rats found a loss of CB1 receptor expression in the nigrostriatal pathway following the lesion [4], while other rodent studies of dopamine depletion or chronic levodopa treatment have reported increases in striatal CB1 receptor mRNA under certain conditions [3]. Together, this body of work suggests that CB1 receptor signaling is not static in parkinsonian models, but the precise pattern of change, and what it means functionally, has not been fully resolved and appears to depend heavily on experimental conditions.
Beyond receptor expression, some preclinical studies have tested whether directly manipulating the ECS affects neurodegeneration or motor behavior in these models. A cannabinoid receptor agonist, WIN55,212-2, was reported in one study to reduce the loss of dopaminergic neurons in the MPTP mouse model [5]. Similarly, increasing levels of the endocannabinoid 2-AG, by inhibiting the enzyme that breaks it down, was associated with neuroprotective effects in the MPTP mouse model in another study [6]. Other preclinical work has focused on the CB2 receptor, which is expressed at much lower levels in the healthy brain but appears to be upregulated in activated microglia and astrocytes, the immune cells of the central nervous system, following dopaminergic injury. Several rodent studies have reported that CB2 receptor activation or overexpression is associated with reduced neuroinflammatory markers and less pronounced dopaminergic cell loss after toxin exposure, leading some researchers to propose that CB2-targeted approaches might have a role in modulating neuroinflammatory processes relevant to Parkinson's disease [3].
These findings are preliminary and preclinical in nature. Animal models of Parkinson's disease, whatever their value for studying specific mechanisms, do not fully replicate the human disease, which develops gradually over decades and involves widespread pathology beyond the dopaminergic system, including the accumulation of misfolded alpha-synuclein protein. Findings of neuroprotection or behavioral improvement in mice or rats following selective toxin exposure do not necessarily translate into clinical benefit in people, and many promising preclinical neuroprotective strategies in Parkinson's disease research have not succeeded when tested in human trials. Researchers who conduct this work are generally careful to frame it as hypothesis-generating rather than as direct evidence for human treatment.
Evidence from human postmortem and brain imaging studies
A smaller number of studies have examined the ECS directly in human brain tissue or in living patients using imaging techniques, which allows researchers to ask whether the receptor changes observed in animal models also occur in people with Parkinson's disease.
One postmortem study examined brain tissue from the substantia nigra and putamen of people who had died with Parkinson's disease, compared with tissue from people without neurological disease. The researchers found that CB1 receptor gene expression was unchanged in the substantia nigra but significantly higher in the putamen of the Parkinson's disease group, while CB2 receptor gene expression was increased in the substantia nigra but decreased in the putamen, and the enzyme that breaks down 2-AG showed the opposite regional pattern. The same study also found that CB2 receptors localized to astrocytes, rather than neurons or microglia, in the substantia nigra of both groups [1]. The authors interpreted these region-specific and receptor-specific changes as evidence that the ECS is altered in the Parkinson's disease brain, though they also noted that the functional consequences of these particular changes remain unclear and that further research would be needed to understand their significance [1].
Brain imaging research using positron emission tomography (PET) has also been used to study CB1 receptor availability in living patients. One PET study using a CB1-selective radioligand found that people with Parkinson's disease who had temporarily stopped their usual dopaminergic medication showed significantly lower CB1 receptor availability across several brain regions, including the thalamus and sensorimotor and parietal cortex, compared with healthy controls; when the same patients were scanned again while taking their usual medication, CB1 receptor availability moved closer to levels seen in controls [7]. This raises the possibility that at least some of the CB1 receptor changes observed in Parkinson's disease may be linked to dopaminergic medication status rather than being a fixed feature of the disease itself, a distinction that still requires further clarification through additional studies.
Taken as a whole, human tissue and imaging studies support the broader premise that ECS signaling is altered in Parkinson's disease, but the studies remain few in number, involve relatively small samples of postmortem or living patients, and do not establish whether these ECS changes are a cause, a consequence, or a compensatory response to the disease process.
What survey and observational research has found in people with Parkinson's disease
Separately from mechanistic research, a number of surveys have asked people living with Parkinson's disease about their own use of cannabis and their perceptions of its effects. These studies provide a different type of evidence: self-reported, real-world experience rather than controlled experimentation.
One of the earlier surveys, conducted in the Czech Republic, asked people with Parkinson's disease who used cannabis about perceived changes in their motor symptoms; some respondents reported subjective improvement in symptoms such as rigidity, tremor, and bradykinesia, but the study relied on retrospective self-report from a self-selected group of cannabis users, without any placebo comparison or blinded assessment [13].
More recently, a large US survey distributed through the Parkinson's Foundation to over 7,600 people with Parkinson's disease received 1,064 complete responses. About a quarter of respondents (24.5%) reported using cannabis within the previous six months, most often for non-motor symptoms such as anxiety (45.5%), pain (44.0%), and sleep disturbance (44.0%), as well as motor symptoms including stiffness and tremor. Among users, a substantial proportion reported moderate or considerable perceived improvement in the severity of these symptoms. At the same time, nearly a quarter of users (23.0%) reported discontinuing cannabis in the same period, most commonly citing a lack of symptom improvement as the reason, and most users (around two-thirds) had never received guidance on cannabis use from a licensed medical provider. Among the 75.5% of respondents who did not use cannabis, the most common reason given was a lack of scientific evidence supporting its efficacy [12]. The study's authors were explicit that their results reflect subjective, self-reported experience rather than controlled clinical evidence, and they specifically called for further controlled research to clarify whether the benefits reported by users would hold up under rigorous testing [12].
These survey findings are useful for understanding patient behavior, motivations, and perceived experience, and they help explain why researchers have pursued more controlled clinical studies. However, surveys of this kind carry well-recognized limitations: they rely on self-report rather than objective clinical measurement, they lack a placebo comparison group, they are subject to recall bias and response bias (people who feel cannabis helped them may be more likely to respond to a survey about cannabis use), and respondents typically used varying and often unknown formulations, doses, and routes of administration of cannabis, making it difficult to draw conclusions about any specific product or dose.
What small clinical trials have found
A limited number of controlled clinical trials have tested specific cannabinoid compounds in people with Parkinson's disease, and their results have been mixed.
One of the earliest controlled trials tested nabilone, a synthetic cannabinoid that activates CB1 receptors, in a small randomized, double-blind, placebo-controlled crossover study of seven people with Parkinson's disease and levodopa-induced dyskinesia. The researchers reported a significant reduction in dyskinesia severity with nabilone compared with placebo, based on the hypothesis that cannabinoid receptor activation in the basal ganglia might dampen the overactive signaling associated with dyskinesia [8]. Given the very small sample size, this result was described by the investigators as preliminary and in need of replication in larger studies.
A subsequent, larger randomized, double-blind, placebo-controlled crossover trial tested an oral cannabis extract (containing both THC and CBD) in 19 people with Parkinson's disease and levodopa-induced dyskinesia, following a separate dose-escalation safety phase in six additional patients. In contrast to the earlier nabilone pilot study, this trial found no objective or subjective improvement in dyskinesia or in parkinsonism with the cannabis extract compared with placebo [9]. The contrast between these two studies illustrates the mixed and sometimes contradictory nature of the clinical trial evidence in this area, and researchers have noted that differences in the specific cannabinoid compound, dose, and outcome measures used may partly explain the discrepancy.
A separate small exploratory double-blind trial examined cannabidiol (CBD), a non-intoxicating cannabinoid, in 21 people with Parkinson's disease without dementia or psychiatric comorbidities, divided into three groups of seven receiving placebo, CBD 75 mg per day, or CBD 300 mg per day. The study assessed motor symptoms, well-being, and quality of life, and reported improvement in quality of life measures at the higher CBD dose, without a corresponding change in motor symptom scores; the authors described the study as exploratory given its very small group sizes and noted that larger, controlled studies would be needed before conclusions could be drawn about efficacy [10].
More recently, a randomized, placebo-controlled trial of nabilone focused specifically on non-motor symptoms in 47 people with Parkinson's disease using an enriched-enrollment, randomized-withdrawal design. The study reported that nabilone was associated with improvement on a composite non-motor symptom scale compared with placebo, with the effect appearing to be driven primarily by improvements in anxious mood and nighttime sleep problems, rather than a broad effect across all non-motor symptoms [11]. Side effects, including dizziness and sedation, were reported in a meaningful proportion of participants across several of these trials, underscoring that cannabinoid compounds are not free of adverse effects in this population.
Across all of these trials, sample sizes have been small, ranging from single digits to several dozen participants, follow-up periods have generally been short, and formulations and doses have varied considerably from one study to the next. Some trials used whole cannabis extract, others used isolated CBD, and others used synthetic cannabinoid receptor agonists such as nabilone, which do not necessarily behave identically to naturally occurring cannabinoids or to each other. Larger, adequately powered, placebo-controlled trials with standardized formulations remain limited, and existing systematic reviews of this literature have generally concluded that the evidence is inconsistent and insufficient to support any specific cannabinoid-based treatment recommendation for Parkinson's disease at this time.
Where the research currently stands
Taken together, the rationale for studying the ECS in Parkinson's disease rests on solid basic neuroscience: CB1 receptors are densely expressed in the basal ganglia circuitry disrupted by the disease, and the ECS is positioned to modulate both the excitatory and inhibitory signaling pathways involved in motor control. Preclinical studies in animal and cell models have reported changes in cannabinoid receptor expression following dopaminergic injury, along with some evidence of neuroprotective or anti-inflammatory effects from cannabinoid receptor manipulation, though these findings have not been consistent across all models and have not yet been shown to translate into human benefit. Human postmortem and imaging studies support the idea that ECS signaling is altered in Parkinson's disease, but the mechanistic and clinical significance of these alterations is still being worked out. Patient surveys indicate that a meaningful minority of people with Parkinson's disease already use cannabis, frequently for non-motor symptoms, and often without medical guidance, while also reporting inconsistent and sometimes disappointing results. Small clinical trials of specific cannabinoid compounds have produced mixed findings, some suggesting modest benefit for particular symptoms such as dyskinesia, anxiety, or sleep, and others showing no benefit at all, generally within study designs too small or short to be considered definitive.
Researchers in this field have consistently called for larger, well-controlled trials using standardized formulations and doses, alongside continued basic and translational research to clarify how, and under what circumstances, ECS signaling changes in Parkinson's disease. Until such research is available, the endocannabinoid system remains an active and legitimate area of scientific inquiry in Parkinson's disease, not an established or recommended treatment approach. People with Parkinson's disease who are curious about this area of research, or who are considering cannabis use for any reason, are encouraged to discuss it openly with their neurologist, who can help weigh the limited and mixed evidence against individual health circumstances, current medications, and local legal considerations.
Educational disclaimer: This article summarizes published research for educational purposes only. It is not medical advice and should not be used as the basis for any treatment decision. Parkinson's disease and its management are highly individualized; please talk with your neurologist or movement disorder specialist before making any changes to your care.
References
Navarrete F, García-Gutiérrez MS, Aracil-Fernández A, Lanciego JL, Manzanares J. Cannabinoid CB1 and CB2 Receptors, and Monoacylglycerol Lipase Gene Expression Alterations in the Basal Ganglia of Patients with Parkinson's Disease. Neurotherapeutics. 2018;15(2):459-469. https://doi.org/10.1007/s13311-018-0603-x
Basavarajappa BS, Shivakumar M, Joshi V, Subbanna S. Endocannabinoid system in neurodegenerative disorders. J Neurochem. 2017;142(5):624-648. https://doi.org/10.1111/jnc.14098
Wang M, Liu H, Ma Z. Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease. Front Cell Neurosci. 2022;16:832854. https://doi.org/10.3389/fncel.2022.832854
Walsh S, Mnich K, Mackie K, Gorman AM, O'Neill C, Fagan SG. Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. Brain Res Bull. 2010;81(6):543-548. https://pubmed.ncbi.nlm.nih.gov/20079412/
Price DA, Martinez AA, Seillier A, et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci. 2009;29(11):2177-2186. https://pubmed.ncbi.nlm.nih.gov/19490092/
Mounsey RB, Mustafa S, Robinson L, et al. Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Exp Neurol. 2015;273:36-44. https://doi.org/10.1016/j.expneurol.2015.07.024
Ajalin RM, Al-Abdulrasul H, Tuisku JM, et al. Cannabinoid Receptor Type 1 in Parkinson's Disease: A Positron Emission Tomography Study with [18F]FMPEP-d2. Mov Disord. 2022;37(8):1673-1682. https://doi.org/10.1002/mds.29117
Sieradzan KA, Fox SH, Hill M, Dick JPR, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 2001;57(11):2108-2111. https://doi.org/10.1212/WNL.57.11.2108
Carroll CB, Bain PG, Teare L, et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004;63(7):1245-1250. https://doi.org/10.1212/01.WNL.0000140288.48796.8E
Chagas MHN, Zuardi AW, Tumas V, et al. Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial. J Psychopharmacol. 2014;28(11):1088-1098. https://doi.org/10.1177/0269881114550355
Peball M, Krismer F, Knaus HG, et al. Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. Ann Neurol. 2020;88(4):712-722. https://doi.org/10.1002/ana.25864
Feeney MP, Bega D, Kluger BM, Stoessl AJ, Evers CM, De Leon R, Beck JC. Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US. NPJ Parkinsons Dis. 2021;7(1):21. https://doi.org/10.1038/s41531-021-00165-y
Venderová K, Růžička E, Voříšek V, Višňovský P. Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms. Mov Disord. 2004;19(9):1102-1106. https://doi.org/10.1002/mds.20111